Apollomics vs Glycyx
Apollomics
We are a biopharmaceutical company committed to the discovery and development of mono- and combination cancer therapies
26 employees · est. 2015 · Foster City, United States
Glycyx
Restoring immune response in cancer: reversing Opioid-Induced Immunodeficiency to enhance immunotherapy efficacy
3 employees · est. 2020 · San Francisco, United States
Apollomics is the older company (2015 vs 2020); Apollomics is the larger of the two.
Side-by-Side Comparison
| Metric | Apollomics | Glycyx |
|---|---|---|
| Founded | ||
| Founded | 2015 older | 2020 |
| Headquarters | ||
| Headquarters | Foster City, United States | San Francisco, United States |
| Employees | ||
| Employees | 26 larger | 3 |
| Industry | ||
| Industry | Biotechnology, Health Care, Pharmaceutical | Biopharma, Biotechnology, Pharmaceutical |
| Funding Stage | ||
| Funding Stage | Post-IPO Equity | Series A |
| Total Funding | ||
| Total Funding | $262.60M | $7.10M |
| Funding Rounds | ||
| Funding Rounds | 5 | 3 |
| Services | ||
| Services | Not tracked yet | Development of therapies that restore immune function, Combination treatments with immune checkpoint inhibitors, Enhanced T-cell infiltration into tumors, Inhibition of opioid-induced immune suppression |
| Target Customers | ||
| Target Customers | Not tracked yet | Cancer patients, Healthcare providers, Oncologists, Pharmaceutical companies |
| Taxonomy | ||
| Taxonomy | Biopharmaceutical CompanyOncology TherapiesCombination TherapiesCancer TreatmentDrug DevelopmentImmune System +8 | Cancer TreatmentImmunotherapyOpioid-Induced ImmunodeficiencyImmune Checkpoint InhibitorsPeripherally Restricted Opioid AntagonistPhase 2 Clinical Trials +8 |
| Website | ||
| Website | apollomicsinc.com | glycyx.com |
About Apollomics
Apollomics is a biopharmaceutical company with a clear mission to discover and develop mono- and combination cancer therapies. Established in 2016, Apollomics has made strategic moves to operate in both the U.S. and China, aiming to harness synergies by collaborating with biotechnology companies in...
About Glycyx
Glycyx, a highly innovative biotech firm founded in 2020 and headquartered in the United States, is tackling a critical yet often overlooked challenge in cancer treatment—opioid-induced immunodeficiency that diminishes the efficacy of immunotherapy. Known as Opioid-Induced Immunotherapy Failure (OII...
Also comparing in this category
Comparing more than these two?
Get Apollomics, Glycyx and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.
How does Apollomics compare?
A PDF of Apollomics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Rival Readout
Comparing competitors? We do this properly.
10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.
Frequently Asked Questions
Compare Apollomics with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at Apollomics on 12 Sep 2024, and Glycyx on 11 Mar 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.